Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms Liberty-AD-HAFT
- Sponsors Regeneron Pharmaceuticals
- 16 Jan 2024 According to Sanofi media release, based on data from this study the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent (dupilumab).
- 18 Mar 2023 Results presented in the Regeneron Pharmaceuticals Media Release.
- 18 Mar 2023 Primary endpoint has been met. (Proportion of patients achieving an Investigator Global Assessment (IGA) (hand and foot) score of 0 or 1), according to a Regeneron Pharmaceuticals media release.